Publication | Open Access

Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsDarunavir VersusVirologyStandard-of-care Antiretroviral RegimensAntiviral TherapyPharmacotherapyAntiviral DrugHivMedicine